1.
Maria Grazia Bernengo, Pietro Quaglino, Alessandra Comessatti, Michela Ortoncelli, Mauro Novelli, Francesco Lisa, Maria Teresa Fierro. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92(6):784-794; https://doi.org/10.3324/haematol.11127.